Edition:
India

Allergan plc (AGN.N)

AGN.N on New York Stock Exchange

171.87USD
12 Dec 2017
Change (% chg)

$-0.89 (-0.52%)
Prev Close
$172.76
Open
$173.11
Day's High
$174.00
Day's Low
$171.66
Volume
436,421
Avg. Vol
628,428
52-wk High
$256.78
52-wk Low
$160.09

Chart for

About

Allergan plc is a specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of brand name pharmaceutical products, medical aesthetics, biosimilar and over-the-counter pharmaceutical products. The Company operates through three segments: US Specialized Therapeutics, US... (more)

Overall

Beta: 1.17
Market Cap(Mil.): $69,117.80
Shares Outstanding(Mil.): 334.31
Dividend: 0.70
Yield (%): 1.35

Financials

  Industry Sector
P/E (TTM): -- 31.14 16.44
EPS (TTM): -- -- --
ROI: -- 14.86 10.62
ROE: -- 16.28 14.20

Teva Pharm to unveil restructuring plan on Thursday: report

TEL AVIV Israel-based Teva Pharmaceutical Industries will unveil a restructuring plan on Thursday that will include layoffs, the Calcalist financial news website said on Wednesday.

1:30pm IST

Teva Pharm to unveil restructuring plan on Thursday - report

TEL AVIV, Dec 13 Israel-based Teva Pharmaceutical Industries will unveil a restructuring plan on Thursday that will include layoffs, the Calcalist financial news website said on Wednesday.

1:23pm IST

BRIEF-Allergan Receives FDA Clearance For The CoolSculpting Treatment To Improve Appearance Of Lax Tissue In The Double Chin

* ALLERGAN RECEIVES FDA CLEARANCE FOR THE COOLSCULPTING TREATMENT TO IMPROVE APPEARANCE OF LAX TISSUE IN THE DOUBLE CHIN Source text for Eikon: Further company coverage:

12 Dec 2017

BRIEF-Repros Therapeutics Announces Acquisition By Allergan

* REPROS THERAPEUTICS INC.® ANNOUNCES ACQUISITION BY ALLERGAN PLC

12 Dec 2017

UPDATE 2-Teva considering cutting up to 10,000 jobs - Bloomberg

Dec 8 Teva Pharmaceutical Industries Ltd is considering cutting up to 10,000 jobs as CEO Kare Schultz seeks to reduce $1.5 billion to $2 billion in costs over the next two years, Bloomberg reported, citing people familiar with the matter.

08 Dec 2017

Fitch Affirms Allergan's 'BBB-' Rating; Outlook Stable

(The following statement was released by the rating agency) CHICAGO, December 07 (Fitch) Fitch Ratings has affirmed the ratings of Allergan plc (Allergan; NYSE: AGN) and subsidiaries at 'BBB-'. The Rating Outlook is Stable. Fitch has also affirmed and withdrawn the 'BBB-' IDRs of Allergan's subsidiaries, Warner Chilcott Limited and Allergan Finance LLC. These IDRs are no longer considered by Fitch to be relevant to the agency's coverage. A full list of rating actions, which apply to approximatel

08 Dec 2017

Tech firms tell patent court to ignore Allergan deal with tribe

Over 30 technology companies including Alphabet Inc , Amazon.com Inc and Facebook Inc. on Friday urged a U.S. patent court to disregard drugmaker Allergan Plc's contention that its transfer of some of its patents to a Native American tribe shields them from the court's review.

02 Dec 2017

Tech firms tell patent court to ignore Allergan deal with tribe

Dec 1 Over 30 technology companies including Alphabet Inc, Amazon.com Inc and Facebook Inc. on Friday urged a U.S. patent court to disregard drugmaker Allergan Plc's contention that its transfer of some of its patents to a Native American tribe shields them from the court's review.

02 Dec 2017

UPDATE 1-Teva Pharm says bold, global action needed to steady company

JERUSALEM, Nov 27 Teva Pharmaceutical Industries needs to take "deep, meaningful steps around the world" to secure its future, it said in a letter to the Israeli parliament on Monday, after media reports the company is set to cut thousands of jobs.

27 Nov 2017

UPDATE 2-Teva Pharmaceutical set for major layoffs in Israel, U.S. -report

TEL AVIV, Nov 23 Teva Pharmaceutical is expected to cut up to a quarter of its 6,860-strong workforce in Israel, and a few thousand more staff in the United States, media reported Thursday, though a minister said the figures may not be accurate.

23 Nov 2017

Earnings vs. Estimates